Russian hospital received the first batch of the drug for the treatment of COVID-19 “Aviewer”, it was created on the basis of the Japanese antiviral drug “Favipiravir”. In June, the Russian hospital will receive 60 thousand courses “of Avifauna”, on 11 June announced the Russian direct investment Fund.
The first batch of drugs against the coronavirus got clinics and authorized pharmaceutical organizations of Moscow, Leningrad, Novgorod, Kirov, Nizhny Novgorod regions, the Republic of Tatarstan and Ekaterinburg, noted in the Fund.
“Aviewer” – one of two drugs in the world, was against the coronavirus. It has proven its effectiveness in clinical trials and blocking mechanisms for the propagation of the coronavirus. “Aviewer” may 29, received a registration certificate from the Ministry of health of the Russian Federation and became the world’s first drug on the basis of “Favipiravir”, approved for the treatment of a coronavirus,” – said the Fund.
Clinical trials of a Russian drug showed high efficiency for the treatment of a coronavirus, noted in the FUND. Now undergoing the final stage of a clinical study involving 330 patients at 35 medical centers. Production of “Avifauna” can increase up to two million courses a year.
“Favipiravir” antiviral agent developed in Japan to treat influenza. It has a broad spectrum activity against RNA-containing viruses, including influenza viruses, rhinovirus, respiratory syncytial virus. “Favipiravir” is being studied as a potential agent for the treatment of several other viral infections, including coronavirus infection COVID-19.
Flash coronavirus infection COVID-19 began in December 2019 in China. March 11, 2020, the world health organization declared the spread of the coronavirus pandemic.
According to the Johns Hopkins University, in Russia, the coronavirus has infected 501 800 people, the victims COVID-19 6522 person has recovered 260 649 people.